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Abstract
Objective: To estimate the incidence of failed pregnancy and menstrual irregularities 
among Liberian women who had survived Ebola virus disease (EVD) and to identify 
host- specific and disease- specific factors associated with these outcomes.
Methods: A cross- sectional questionnaire- based study was conducted between August 
10, 2016, and February 7, 2017. The study population comprised 111 women aged 
18–45 years who had survived EVD and were enrolled in the Longitudinal Liberian 
Ebola Survivor study based at the Eternal Love Winning Africa Hospital, Monrovia, 
Liberia. Self- reported data on outcomes related to pregnancy and menstrual changes 
since recovery from EVD were collected.
Results: In all, 29 (26.1%) of the participants had become pregnant since surviving 
EVD. Of the 23 women whose pregnancies continued to term, 10 (43.4%) reported 
live birth, 11 (47.8%) reported spontaneous abortion, and two (8.7%) reported stillbirth. 
Of the 105 women who reported having regular menstruation before EVD, 27 (29.0%) 
reported experiencing irregular menstruation for unknown reasons after EVD. In bivari-
ate logistic models, no associations were found between failed pregnancy or irregular 
menstruation and any of the factors of interest.
Conclusions: Adverse pregnancy outcomes and irregular menstruation were frequently 
reported among EVD survivors in Liberia.
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1  | INTRODUCTION
The 2014–2016 West African Ebola virus disease (EVD) outbreak led 
to the infection of more than 28 600 individuals, a figure that was 
several- fold higher than the total number of all previous known cases 
of EVD combined.1 The case fatality rate of EVD is high (50%–70%); 
nonetheless, affected individuals can survive. Indeed, it is thought that 
there are more than 10 000 survivors of the 2014–2016 EVD out-
break living in Guinea, Liberia, and Sierra Leone.2
Cohorts of survivors have reported persistent clinical and psy-
chological manifestations of EVD. Such post- EVD sequelae were first 
documented among survivors of the 1995 outbreak in the Democratic 
Republic of Congo.3,4 Presentation of post- EVD sequelae vary, both 
by type and severity, but can include arthralgia, ocular complications, 
depression, abdominal pain, and insomnia.2,5–7 Although the mecha-
nisms underlying these clinical complications of EVD remain unknown, 
some studies found an association between the severity of the acute 
illness, as measured by viral load, with sequelae after recovery.8
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Ebola virus can persist in certain immunologically protected parts 
of the body, including semen, the interior compartments of the eye, 
and central nervous system.9–11 Ebola virus RNA has been detected 
in the semen of EVD survivors at more than 2 years after recovery.11 
In addition, sexual transmission of the virus from male survivors to 
their female sexual partners has been identified as the cause of at least 
three cases of EVD recrudescence in West Africa.12
Most studies on the impact of Ebola virus on female reproduction 
have been limited to women who were pregnant at the time of infec-
tion. Fetal or early neonatal death is almost certain to occur among 
women who were pregnant when they developed EVD.13,14 Some evi-
dence suggests that Ebola virus could persist in the uteruses of survi-
vors who were pregnant when they became infected.5 Women who 
experienced spontaneous abortion after discharge from the Ebola 
treatment unit (ETU) had negative blood test results for Ebola virus; 
however, products of conception (i.e. the fetus, placenta, and amniotic 
sac) have tested positive for Ebola virus RNA.5 For women who were 
not pregnant at the time of infection, there is evidence that Ebola virus 
RNA might remain in the vaginal fluid for up to 1 month after the onset 
of symptoms.9
Guidance on the clinical care of EVD survivors released by WHO in 
April 20162 provided anecdotal evidence of stillbirths among women 
who had conceived after EVD, and warned that such pregnancies 
should be treated as high- risk for fetal complications. The same guide-
lines indicated that menorrhagia, metrorrhagia, and amenorrhea had 
been reported by some EVD survivors. However, little research has 
examined the ongoing reproductive health of female EVD survivors 
after recovery from acute infection.6,15,16
The aims of the present study were to estimate the frequency of 
adverse reproductive health outcomes (failed pregnancy and irregular 
menstruation) and to identify factors associated with these outcomes 
among Liberian EVD survivors.
2  | MATERIALS AND METHODS
A cross- sectional questionnaire- based study was conducted between 
August 10, 2016, and February 7, 2017. The population comprised 
women who had survived EVD and were enrolled in the Longitudinal 
Liberian Ebola Survivor study, which was based at the Eternal Love 
Winning Africa (ELWA) Hospital, Monrovia, Liberia. The research pro-
tocol, data collection tools, and consent forms were approved by the 
institutional review boards of the University of North Carolina (Chapel 
Hill, USA) and the University of Liberia Pacific Institute for Research 
and Evaluation (Monrovia, Liberia). All participants provided written 
informed consent before enrolling in the Longitudinal Liberian Ebola 
Survivor study.
Two ETUs were based at ELWA Hospital during the 2014–2016 
EVD outbreak. This hospital has since established a clinic for EVD sur-
vivors in the Monrovia area, where they can undergo evaluation and 
receive treatment for issues related to post- EVD sequelae.
All study participants were recruited from the ELWA Hospital 
Ebola Survivor Clinic and local communities through word of mouth, 
as survivors often told other survivors about the Longitudinal Liberian 
Ebola Survivor study and encouraged them to enroll. Inclusion crite-
ria for the present study were history of EVD (evidenced by a dis-
charge certificate from an ETU); female sex; and age 18–45 years. 
All women who met these criteria also had to be willing and able to 
consent to participation. There were no specific exclusion criteria for 
the current analysis.
Although participants in the Longitudinal Liberian Ebola 
Survivor study attended ELWA Hospital every 3 months, the data 
used for the present study were cross- sectional. These data were 
collected from an interviewer- administered questionnaire (Box S1). 
All interviews were conducted in Liberian English in a private room 
at ELWA Hospital.
In the present study, the outcomes ‘spontaneous abortion’ and 
‘stillbirth’ were self- defined by the participants, rather than using the 
WHO definition of fetal death occurring before or after 28 weeks of 
gestation.17 The term ‘failed pregnancy’ was used to include both still-
births and spontaneous abortions.
Participants were categorized as experiencing ‘regular menstrua-
tion post- EVD’ if they reported having regular menstruation (cycles 
lasting approximately 30 days) both before and after infection with 
Ebola virus. Women were categorized as experiencing ‘irregular men-
struation post- EVD for unknown reason’ if they reported having reg-
ular menstruation before infection but irregular or no menstruation 
at any point between ETU discharge and data collection, and did not 
identify a reason for this change. Women who reported irregular men-
struation for unknown reason were further categorized based on their 
qualitative description of menstrual change. The definitions used for 
menstrual irregularities are outlined in Table 1.
All data were entered into Access version 16.0 (Microsoft, 
Redmond, WA, USA) and then imported into SAS version 9.4 (SAS 
Institute, Cary, NC, USA) for the analysis. The percentage of women 
reporting the outcomes of interest (failed pregnancy and irregular 
menstruation for unknown reason) was calculated. Bivariate and mul-
tivariable logistic regression models were used to identify potential 
factors associated with failed pregnancy and irregular menstruation. 




Absent or irregular menstruation owing 
to use of hormonal contraception, 




Absent or irregular menstruation with-
out a plausible explanation or reason
Amenorrhea Absence of menstruation for ≥3 mo
Oligomenorrhea Infrequent menstruation, reduced dura-
tion of flow, light or scanty flow
Dysmenorrhea Experience of abdominal pain, cramp-
ing, or backache during menstruation
Menorrhagia Frequent menstruation, increased dura-
tion of flow, and/or heavy flow
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Odds ratios and 95% confidence intervals were estimated to com-
pare variables by pregnancy and menstruation outcomes. Adjusted 
ORs that controlled for the variables of maternal age or duration 
of illness owing to EVD were also used. Variables were considered 
for inclusion in the current analysis based on the existing literature 
regarding factors related to clinical sequelae among EVD survi-
vors.8,15,18–20 They included duration of illness owing to EVD; the 
number of post- EVD sequelae reported (e.g. vision issues, auditory 
issues, joint pain, etc.); maternal age at the time of enrolling in the 
Longitudinal Liberian Ebola Survivor study; and time between ETU 
discharge and conception.
3  | RESULTS
A total of 111 women were included in the present study. Their char-
acteristics are outlined in Table 2. The mean age at the time of EVD 
infection was 29.4 years. On average, interviews were conducted 
at 709 days after ETU discharge; the mean age at interview was 
31.6 years.
A total of 29 (26.1%) participants reported becoming pregnant 
at least once after EVD (Fig. 1 and Table 3). Four (13.8%) of these 
women had become pregnant twice since ETU discharge; however, 
the current analysis was limited to the outcomes of the first pregnancy 
following EVD for each woman. As shown in Figure 1, of the 23 preg-
nancies continued to terminus for which outcome data were available, 
13 (56.5%) resulted in either spontaneous abortion (n=11, 47.8%) or 
stillbirth (n=2, 8.7%). The mean reported gestational age at the time of 
spontaneous abortion was 11 weeks. Both stillbirths had a reported 
gestational age of 40 weeks, suggesting that fetal death had occurred 
at the time of labor and delivery.
Of the 93 women who reported having regular menstruation 
before EVD, 27 (29.0%) reported that their menstruation became 
irregular after EVD due to unknown reasons (Fig. 2 and Table 3). A total 
of 22 (81.5%) menstrual irregularities were characterized as amenor-
rhea or oligomenorrhea (Fig. 3). Dysmenorrhea and/or menorrhagia 
were reported by four (14.8%) women.
TABLE  2 Characteristics of the participants (n=111).a
Characteristic Distribution
Age at time of EVD, y 29.4 ± 7.2
Age at time of the present study, y 31.6 ± 7.3
Duration of EVD, d 28.2 ± 13.9







Post- secondary 11 (9.9)
Relationship status
Not in a relationship 11 (9.9)
In a relationship, not married 78 (70.3)
In a relationship, married 22 (19.8)
Habitation status
Living alone 24 (21.6)
Living with partner or family 87 (78.4)
Abbreviations: ETU, Ebola treatment unit; EVD, Ebola virus disease.
aValues are given as mean ± SD or number (percentage).
F IGURE  1 Study population for analyzing pregnancy outcomes. 
Abbreviation: EVD, Ebola virus disease.
Participants in 
Longitudinal Liberian 



















Female, 18-45 years 
(n=111)
TABLE  3 Reproductive health outcomes among the participants 




Live birth 10 (34.5)
Stillbirth 2 (6.9)
Spontaneous abortion 11 (37.9)
Elective induced abortion 3 (10.3)
Currently pregnant 2 (6.9)
Unknown 1 (3.5)
Regular menstruation before EVD 105 (94.6)
Menstruation status after EVD
Regular menstruation 66 (62.9)
Irregular menstruationb, known reasonc 12 (11.4)
Irregular menstruationb, unknown reason 27 (25.7)
Abbreviation: EVD, Ebola virus disease.
aValues are given as number (percentage).
bIrregular menstruation included no menstruation; light or infrequent men-
struation; heavy menstruation; frequent menstruation; and/or abdomen or 
back pain during menstruation.
cKnown reasons for irregular menstruation included pregnancy; breast-
feeding; have reached menopause at the age of 45 y or older; or using 
hormonal contraceptives.
     |  215Godwin ET AL.
Table 4 shows the association of demographic and EVD- related 
factors with pregnancy outcomes. In bivariate logistic models, no 
associations were found between failed pregnancy and any of the 
factors of interest. In addition, no associations were found between 
pregnancy outcome and potential factors after adjusting for age of the 
mother or duration of EVD.
Table 5 shows the association of demographic and EVD- related 
factors with menstruation outcomes. No bivariate associations were 
found between menstrual irregularities due to unknown reasons and 
any of the factors of interest. These associations remained null even 
after adjusting for maternal age.
4  | DISCUSSION
The present study found high rates of pregnancy failure and irregu-
lar menstruation among Liberian survivors of EVD. These findings 
highlighted the substantial long- term impact of EVD among female 
survivors after acute infection. As such, they represent an important 
contribution to the previous literature regarding reproductive health 
outcomes in this population.
The observed rate of failure of first pregnancy after EVD owing 
to spontaneous abortion (47.8%) was higher than the reported rate 
of 15%–20% for spontaneous abortion in general populations21; 
however, no substantiated data are available for general popula-
tions in West Africa. In addition, the current finding that 8.7% of 
first pregnancies after EVD resulted in stillbirth is also greater than 
the 36 stillbirths per 1000 live births (3.6%) estimated for preg-
nancies in Sub- Saharan Africa.22 A small qualitative study that con-
ducted in- depth interviews among 13 female survivors, who had 
conceived after EVD and continued to terminus found no cases of 
spontaneous abortion but three (23%) cases of stillbirth, suggesting 
that pregnancy failure was increased in this cohort.16 The present 
findings were also consistent with another study of female survivors 
(n=68) in Liberia, which found increased rates of post- EVD preg-
nancy failure (22.1% for spontaneous abortion and 5.8% for still-
birth).15 However, the present study included pregnancies that were 
conceived up to 4 months later in the post- EVD recovery period. 
Importantly, the results of the present study potentially indicated a 
greater frequency of failed pregnancies (>50%) among female EVD 
survivors than was previously suggested.
The present study found that more than one- quarter of women 
who reported regular menstruation before EVD had experienced 
irregular menstruation after EVD. Oligomenorrhea was the most fre-
quently reported type of menstrual irregularity, followed by amenor-
rhea. The frequency of irregular menstruation found in the present 
study was higher than the 5%–17% rate estimated for women in 
low- income settings,23 and the 16% rate estimated for women in 
rural Gambia.24 A previous Liberian study found that approximately 
half of all EVD survivors assessed had experienced menstrual changes 
after infection16; however, that study did not estimate the frequency 
of amenorrhea, dysmenorrhea, and oligomenorrhea separately. In 
another study of post- EVD menstrual sequelae, 10% of survivors seen 
at 1–3 months after discharge from an ETU reported experiencing 
amenorrhea6; however, this short follow- up period would not have 
captured cases of menstrual irregularity that developed after that 
time. By contrast, the present study had a mean follow- up of approxi-
mately 2 years. Thus, the current findings indicated an excess of men-
strual irregularity among EVD survivors after acute infection when 
compared with the general population in West Africa. Furthermore, 
the present study extended the previous literature by providing spec-
ificity about the types of menstrual irregularity that might develop at 
some time after EVD.
The underlying mechanisms by which Ebola virus infection affects 
pregnancy outcomes and menstruation after EVD remain unclear. 
Sustained immune activation and/or dysregulation might to contrib-
ute to the high incidence of failed pregnancies recorded after EVD.5 
The strong association between immune dysregulation and spon-
taneous abortion in the general population lends credence to this 
hypothesis.25 Inflammation of the placenta has been associated with 
F IGURE  2 Study population for analyzing menstrual outcomes. 
Abbreviation: EVD, Ebola virus disease.
Participants in 
Longitudinal Liberian 















Irregular menstruation post-EVD, 
unknown reason
(n=27)
Female, 18-45 years 
(n=111)
F IGURE  3 Menstrual irregularities among women who reported 
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stillbirth.26 Furthermore, ongoing inflammation after infection could 
provide an etiology for some post- EVD clinical manifestations such as 
arthritis and uveitis.5 Irregular menstruation among EVD survivors in 
the present study could be attributable to multiple underlying factors, 
including weight loss and stress.27 Given that survivors would have 
lost large amounts of weight during the period of acute EVD,3 and are 
likely to have experienced high levels of stress after Ebola, it is plausi-
ble that these factors (in isolation or in combination) could explain the 
menstrual changes observed in the present study. Persistent inflam-
mation following EVD might also contribute to irregular menstruation, 
as menstruation is driven by interactions between ovarian hormones 
and the immune system.28
The current analysis had some limitations. The study population 
comprised only EVD survivors; therefore, the lack of a control group 
(i.e. reproductive- aged women who had not experienced EVD) limited 
the findings to descriptive statistics. The present study was suscep-
tible to selection bias in that individuals who access services at the 
ELWA Hospital Ebola Survivor Clinic might experience more severe 
post- EVD sequelae than EVD survivors who do not access services 
at that hospital. Conversely, the sickest EVD survivors might not have 
been able to travel to ELWA Hospital and so were excluded from the 
present study. Also, the use of self- reported and self- defined data for 
the failed pregnancy outcomes could have resulted in some early still-
births being reported as spontaneous abortions, as the women might 
not have known how to differentiate between these two outcomes. 
One of the greatest limitations was the lack of data on pre- EVD 
pregnancy history. It was unclear how many of the participants had 
experienced a failed pregnancy before EVD, thereby placing them at 
increased risk of failed pregnancy after EVD.27 Finally, the sample size 
(n=111) resulted in small numbers of women reporting on the various 
outcomes of interest. Consequently, the analysis of these outcomes 
for potential associations with other factors, while descriptive, suf-
fered from low statistical power.
In the present study, a substantial proportion of female EVD sur-
vivors in Liberia experienced adverse reproductive health outcomes. 
Additional research is needed to identify the mechanisms by which 
EVD causes these clinical sequelae among survivors and the unique 
ways in which EVD affects women. Future studies on post- EVD 
sequelae should include specific questions regarding menstruation 
and pregnancy, as well as the collection of biomarkers of reproductive 
health. In addition, programs offering psychosocial or clinical support 
to female EVD survivors should include counseling on potential repro-
ductive health complications.
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